Atacicept 25 mg

DRUG2 trials

Sponsors

EMD Serono, EMD Serono Research & Development Institute, Inc.

Conditions

IgA NephropathyRelapsing Multiple Sclerosis

Phase 2

Atacicept in Multiple Sclerosis Extension Study, Phase II

TerminatedNCT00853762

EMD SeronoRelapsing Multiple Sclerosis

Start: 2009-03-31End: 2011-02-28Updated: 2017-03-20

Efficacy and Safety of Atacicept in IgA Nephropathy

TerminatedNCT02808429

EMD Serono Research & Development Institute, Inc.IgA Nephropathy

Start: 2017-01-31End: 2020-02-07Updated: 2021-02-25

Related Papers

#3848 ORIGIN TRIAL: 24-WK PRIMARY ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PH2B STUDY OF ATACICEPT IN PATIENTS WITH IGAN

Nephrology Dialysis Transplantation2023-06-0113 citations

Randomized Phase II JANUS Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria.

2022-05-2671 citations

MO039THE 24-WEEK INTERIM ANALYSIS RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY OF ATACICEPT IN PATIENTS WITH IGA NEPHROPATHY AND PERSISTENT PROTEINURIA

Nephrology Dialysis Transplantation2020-06-0113 citations

Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.

2014-03-06250 citations